Patients with diabetes have an up to 50% increased risk of cardiovascular (CV) disease (CVD) compared to individuals without diabetes. Optimisation of glycaemic control can reduce the long-term development of CVD and mortality. Rafal Ziecina et al. of Worldwide conclude that wider application of digital technology will be required to accelerate the development, testing and delivery of crucial new therapies for patients with CVD.